Table 2.
Ongoing clinical trials evaluating checkpoint inhibitor plus VEGF TKI in unresectable gastroesophageal cancer
| NCT number | Status | Interventions | Phases | Treatment setting | Results |
|---|---|---|---|---|---|
| NCT02999295 | Completed | Nivolumab + ramucirumab | Phase 1/2 | 2nd line |
ORR: 26.7% DCR: 62.2% Grade 3–4 AE: 33/46 No deaths |
| NCT03406871 | Active, not recruiting | Nivolumab + regorafenib | Phase 1 | 3rd line |
ORR: 44% mPFS: 5.6 mo mOS: 12.3 mo Grade 3–4 AEs: 20/50 3 DLTs with Rego 160 mg |
| NCT02572687 | Active, not recruiting | Durvalumab + ramucirumab | Phase 1 | 2nd line |
ORR: 21% mOS: 2.6 mo mPFS: 12.4 mo Grade 3–4 AE: 37.9% |
| NCT02443324 | Active, not recruiting | Pembrolizumab + ramucirumab | Phase 1 | 4th line |
ORR: 7% DCR: 44% Grade 3–4 AE: 11/29 |
| NCT03609359 | Active, not recruiting | Pembrolizumab + lenvatinib | Phase 2 | 1st of 2nd line |
ORR: 69% DCR: 100% mPFS: 6.9 mo Grade 3–4 AE: 14/29 No Gr 4–5 AE |
| NCT02942329 | Unknown | SHR1210 + apatinib | Phase ½ | 2nd line |
ORR: 16% DCR: 78% Grade 3–4 AE: 20/33* 4/43 DLTs |
| NCT03539822 | Recruiting | Cabozantinib + durvalumab | Phase 1/2 | 3rd line |
ORR: 25% DCR: 85% Median time to progression: 16 weeks No DLTs |
| NCT04267549 | Recruiting | Sintilimab + apatinib + chemotherapy | Phase 2 | 2nd line | Not yet reported |
| NCT04182724 | Recruiting | Camrelizumab + apatinib + nab-paclitaxel | Phase 1/2 | 2nd line | Not yet reported |
| NCT04006821 | Recruiting | Camrelizumab + apatinib | Phase 2 | 2nd line | Not yet reported |
| NCT03995017 | Recruiting | Rucaparib + ramucirumab + nivolumab | Phase 1/2 | 2nd line | Not yet reported |
| NCT03966118 | Recruiting | Avelumab + ramucirumab + paclitaxel | Phase 2 | 2nd line | Not yet reported |
| NCT03813784 | Recruiting | SHR-1210 + capecitabine + oxaliplatin then shr-1210 + apatinib versus capecitabine + oxaliplatin | Phase 3 | 1st line | Not yet reported |
| NCT03797326 | Recruiting | Pembrolizumab + lenvatinib | Phase 2 | 3rd line | Not yet reported |
| NCT03603756 | Recruiting | SHR-1210 + apatinib + chemotherapy | Phase 2 | 1st line | Not yet reported |
| NCT03475953 | Recruiting | Regorafenib + avelumab | Phase 1/2 | 2nd line | Not yet reported |
| NCT03321630 | Recruiting | Lenvatinib + pembrolizumab | Phase 2 | 2nd line | Not yet reported |
| NCT03170960 | Recruiting | Cabozantinib + atezolizumab | Phase 1/2 | 2nd line | Not yet reported |
| NCT02734004 | Active, not recruiting | MEDI4736 + olaparib ± bevacizumab | Phase 1/2 | 2nd line | Not yet reported |
*Toxicity results of overall population including patients with hepatocellular cancer patients. Grade 3–4 AEs represent incidence of patients receiving recommended phase II trial dose